Literature DB >> 1952860

Comparison of the inoculum effect of cefoxitin and other cephalosporins and of beta-lactamase inhibitors and their penicillin-derived components on the Bacteroides fragilis group.

E J Goldstein1, D M Citron, C E Cherubin.   

Abstract

We compared the inoculum effects for 109 recent clinical isolates of the Bacteroides fragilis group of cefoxitin, cefotetan, ceftizoxime, ceftriaxone, and three beta-lactamase inhibitors (clavulanic acid, sulbactam, and tazobactam) and their penicillin-derived components. Bactericidal activity was assayed and morphologic changes were monitored for selected strains exhibiting a large inoculum effect. Ceftizoxime demonstrated the largest inoculum effect, followed by cefotetan and ceftriaxone. The large inoculum effect of ceftizoxime and ceftriaxone was correlated with filamentous transformation at the high inoculum (10(8) CFU/ml) and lack of bactericidal activity suggesting drug destruction or inactivation. Cefotetan was bactericidal for B. fragilis isolates but not for other members of the B. fragilis group. Cefoxitin showed the least inoculum effect and was consistently bactericidal at high (10(8) CFU/ml), standard (10(6) CFU/ml), and low (10(4) CFU/ml) inocula, followed by ampicillin-sulbactam. Piperacillin-tazobactam and ticarcillin-clavulanic acid showed an intermediate inoculum effect. The degree of inoculum effect observed generally correlated with bactericidal activity at all inocula.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1952860      PMCID: PMC245283          DOI: 10.1128/AAC.35.9.1868

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

Review 1.  Inoculum effect.

Authors:  I Brook
Journal:  Rev Infect Dis       Date:  1989 May-Jun

2.  Comparison of the inoculum effects of members of the family Enterobacteriaceae on cefoxitin and other cephalosporins, beta-lactamase inhibitor combinations, and the penicillin-derived components of these combinations.

Authors:  E J Goldstein; D M Citron; C E Cherubin
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191

3.  Characterization of beta-lactamases from non-Bacteroides fragilis group Bacteroides spp. belonging to seven species and their role in beta-lactam resistance.

Authors:  P C Appelbaum; A Philippon; M R Jacobs; S K Spangler; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

4.  Enhanced antimicrobial activity of old and new beta-lactams against cefoxitin-resistant Bacteroides fragilis group isolates by beta-lactamase inhibitors.

Authors:  K E Aldridge; A Henderberg; C V Sanders
Journal:  J Antimicrob Chemother       Date:  1990-05       Impact factor: 5.790

5.  Comparative activities of newer beta-lactam agents against members of the Bacteroides fragilis group.

Authors:  G J Cuchural; F P Tally; N V Jacobus; T Cleary; S M Finegold; G Hill; P Iannini; J P O'Keefe; C Pierson
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

6.  Comparison of in vitro antibiograms of Bacteroides fragilis group isolates: differences in resistance rates in two institutions because of differences in susceptibility testing methodology.

Authors:  K E Aldridge; H M Wexler; C V Sanders; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1990-01       Impact factor: 5.191

7.  Short prereduced anaerobically sterilized (PRAS) biochemical scheme for identification of clinical isolates of bile-resistant Bacteroides species.

Authors:  D M Citron; E J Baron; S M Finegold; E J Goldstein
Journal:  J Clin Microbiol       Date:  1990-10       Impact factor: 5.948

8.  Piperacillin/tazobactam (YTR 830) combination. Comparative antimicrobial activity against 5889 recent aerobic clinical isolates and 60 Bacteroides fragilis group strains.

Authors:  R N Jones; M A Pfaller; P C Fuchs; K Aldridge; S D Allen; E H Gerlach
Journal:  Diagn Microbiol Infect Dis       Date:  1989 Nov-Dec       Impact factor: 2.803

9.  Effect of inoculum size and beta-lactamase production on in vitro activity of new cephalosporins against Haemophilus species.

Authors:  R R Bulger; J A Washington
Journal:  Antimicrob Agents Chemother       Date:  1980-03       Impact factor: 5.191

10.  Effect of Bacteroides fragilis on mortality induced by Escherichia coli in an experimental infection treated with cefotaxime, aztreonam or gentamicin.

Authors:  F Soriano; C Ponte; M Santamaría; C Castilla
Journal:  J Antimicrob Chemother       Date:  1989-03       Impact factor: 5.790

View more
  3 in total

1.  Correlation between in vitro and in vivo activities of GM 237354, a new sordarin derivative, against Candida albicans in an in vitro pharmacokinetic-pharmacodynamic model and influence of protein binding.

Authors:  P Aviles; C Falcoz; M J Guillén; R San Roman; F Gómez De Las Heras; D Gargallo-Viola
Journal:  Antimicrob Agents Chemother       Date:  2001-10       Impact factor: 5.191

Review 2.  Piperacillin/tazobactam. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  H M Bryson; R N Brogden
Journal:  Drugs       Date:  1994-03       Impact factor: 9.546

3.  In vitro activity of FK037, a new parenteral cephalosporin, against anaerobic bacteria.

Authors:  N Kato; H Kato; Y Tanaka; K Bando; K Watanabe; K Ueno
Journal:  Antimicrob Agents Chemother       Date:  1993-05       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.